Bristol-myers Squibb Compnay

Pfizer Corporation

Vanderbilt University

Bristol Meyers Squibb Company

Yong-Jin Wu

Jason M Guernon

Jianliang Shi

Huan He

Kenneth M Boy

John E Macor

Jie Chen

Lorin A Thompson, Iii

Yunhui Zhang

Wei-Guo Su

Takushi Kaneko

Richard Eric Olson

Li-Qiang Sun

Alexandre L'Heureux

Dmitry S Zuev

Guanglin Luo

Carolyn Diane Dzierba

Junqing Guo

Amy C Hart

Brian Lee Venables

Lawrence R Marcin

Li Xu

Craig William Lindsley

P Jeffrey Conn

Michael G Yang

Darren W Engers

Steven H Spergel

Corey R Hopkins

Zili Xiao

David Bertil Frennesson

Samuel Gerritz

Colleen M Niswender

Mendi A Higgins

Shirong Zhu

Shuhao Shi

Matthew Reiser Patton

Xirui Hu

Joe Panarese

Joanne Bronson

Paul Michael Scola

Piyasena Hewawasam

Andrew Charles Good

Sing-Yuen Sit

William John Pitts

Joanne J Bronson

Scott Hunter Watterson

Katharine A Grant-Young

Bingwei Vera Yang

Julie L Engers

Ramkumar Rajamani

Katherine E Brighty

Kyle A Emmitte

Paul R McGuirk

Zhizhen Barbara Zheng

Hua Gong

Gene G Kinney

Hamish A McArthur

Michael E Mertzman

Yazhong Huang

Pierre Dextraze

Hiroko Masamune

Jean-Paul Daris

Nenghui Wang

Carolyn A Weigelt

Murugaiah Andappan Murugaiah Subbaiah

Steven Dworetzky

Shuanghua Hu

Robert G Linde, Ii

Li-Quang Sun

Kathleen T Smyth

Daniel J Durkin

Michael C Mertzman

Jason Guernon

Lorin A Thompson Iii

Lorin A Iii Thompson

Iii Lorin A Thompson

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Triazolopyridinyl compounds as kinase inhibitors

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications. 

Aminopyrrolotriazines as kinase inhibitors

The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (I) 

Acyl sulfonamide NaV1.7 inhibitors

Compounds, including those of the following formula: wherein the variables are defined herein, which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.

Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.

Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: wherein Rand Rare independently hydrogen, or &#x2014;CH; or Rand Rcan join together in a ring by adding &#x2014;(CH)&#x2014;; Ris hydrogen or C-Calkyl; Y and Z are independently a C-C-aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, Calkylamino, Cdialkylamino, haloCalkyl, CN, C-Calkyl or cycloalkyl, C-Calkoxy, &#x2014;C&#x2550;OCalkyl, &#x2014;SOCalkyl, and C-Calkynyl; A is selected from the group of phenyl, benzyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, Calkylamino, Cdialkylamino, haloCalkyl, hydroxyCalkyl, CN, C-Calkyl or cycloalkyl, C-Calkoxy, and C-Calkynyl; L is &#x2014;NHCO&#x2014; or is a single bond; and L and Z together can be absent. 

4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production

The present disclosure provides a series of compounds of the formula (I) 

Compounds for the reduction of &#x3b2;-amyloid production

Compounds of the formula (I) are provided, including pharmaceutically acceptable salts thereof: which modulate &#x3b2;-amyloid peptide (&#x3b2;-AP) production, and are useful in the treatment of Alzheimer's Disease and other conditions affected by &#x3b2;-amyloid peptide (&#x3b2;-AP) production.

Compounds for the reduction of beta-amyloid production

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: 

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: wherein R, R, R, R, R, and Rare independently hydrogen, C-Calkyl or C-Ccycloalkyl;

The present disclosure provides a series of compounds of the formula (I) which reduce &#x3b2;-amyloid peptide (&#x3b2;-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by &#x3b2;-amyloid peptide (&#x3b2;-AP) production.

Bicyclic compounds for the reduction of beta-amyloid production

There is provided a series of macrocyclic diaminopropanes of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R, R, R, m, n, W, X, Y, Z and L as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by &#x3b2;-secretase and, more specifically, inhibit the production of A&#x3b2;-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to &#x3b2;-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

Diaminopropane derived macrocycles as inhibitors of &#x3b2; amyloid production

Growing community of inventors

Madison, CT, United States of America

Yong-Jin Wu